Washington, DC – June 27, 2024 – Cooley successfully prevailed in an inter partes review for Liquidia Technologies, a biopharmaceutical company focused on the development and commercialization of products to treat pulmonary hypertension, in its ongoing patent and trade secret dispute with United Therapeutics Corp. The US Court of Appeals for the Federal Circuit affirmed the Patent Trial and Appeal Board’s finding that all claims of US Patent No. 9,604,901 are invalid as obvious.
Partners Sanya Sukduang and Jonathan Davies led the Cooley team representing Liquidia, along with associates Brittany Cazakoff, Robert Minn and Rachel Preston.
Cooley previously defeated a preliminary injunction filed by United Therapeutics in June 2024, and advised Liquidia on its first product launch in April 2024 and its $53 million initial public offering in August 2023.
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 1,300+ lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.